Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 13/20 | 1.00 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.61 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.61 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.61 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.61 |
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312702 | 1.00 | SPHK1 (1.00) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL1312405 | 1.00 | SPHK1 (1.00) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL1312087 | 1.00 | SPHK1 (1.00) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL1312105 | 1.00 | SPHK1 (1.00) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL1311924 | 1.00 | SPHK1 (1.00) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL1313045 | 1.00 | SPHK1 (1.00) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL1313131 | 1.00 | SPHK1 (1.00) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL12121498 | 1.00 | SPHK1 (1.00) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL1312473 | 0.96 | SPHK1 (0.93) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL1312097 | 0.91 | SPHK1 (0.84) | SPHK1SPHK2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | claimed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | SPHK1, SPHK2, S1PR1 | SPHK1 1/4885SPHK2 2/4885S1PR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.